research May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
research Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Analysis of Cost-effectiveness of 4 Kinds of Projects for Drug Therapy in the Treatment of BPH
Using tamsulosin with finasteride is the most effective and reduces surgery risk for BPH.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research CAN PATIENTS WITH LUTS AND BPH DISCERN CHANGES IN PEAK URINARY FLOW RATE AND DO SUCH CHANGES CONTRIBUTE TO OVERALL SATISFACTION WITH TREATMENT?
Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
research 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
research Lower Urinary Tract Symptoms in the Elderly Male: Choosing Wisely
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
research Finasteride: the first 5 alpha-reductase inhibitor.
research Editorial comment
Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
research MP74-11 TRENDS IN THE PHARMACOTHERAPY OF NOCTURIA, 2016-2021: ANALYSIS OF A LARGE MULTI-INSTITUTIONAL RESEARCH NETWORK
Nocturia cases increased, but medication use declined, suggesting under-treatment.
research Incomplete Recovery of Erectile Function in Rat after Discontinuation of Dual 5‐Alpha Reductase Inhibitor Therapy
Rats had lasting erectile problems after stopping a certain medication.
research Finasterid in der Behandlung der benignen Prostatahyperplasie
Finasteride effectively reduces prostate size and symptoms in most BPH patients.
research Інгібітор 5α-редуктази дутастерид при лікуванні доброякісної гіперплазії передміхурової залози: системний огляд та мета-аналіз
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
research Dutasteride/finasteride
research Terazosin reduced BPH symptoms and finasteride did not
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
research Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides as 5.alpha.-Reductase Inhibitors and Antiandrogens
The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
research [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].
Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
research 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
Persistent ED in Propecia users is not due to abnormal blood flow.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Validated HPTLC method for the simultaneous determination of alfuzosin, terazosin, prazosin, doxazosin and finasteride in pharmaceutical formulations
Method can accurately measure five BPH drugs at once.
research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.